Daurismo (glasdegib) / Pfizer - LARVOL DELTA

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. (PubMed, Leuk Lymphoma) - P1/2 | "Overall, 50 patients were enrolled into one of 6 arms: (A) single agent PF-04518600 (OX40 agonist monoclonal antibody), (B) azacitidine + venetoclax + gemtuzumab ozogamicin (GO), (C) azacitidine + avelumab (anti-PD-L1 monoclonal antibody) + GO, (D) azacitidine + venetoclax + avelumab, (E) azacitidine + avelumab + PF-04518600, and (F) glasdegib + GO. This study shows the feasibility of a conducting a multi-arm trial to efficiently and simultaneously evaluate novel therapies in AML, a needed strategy in light of the plethora of emerging therapies. This trial was registered at www.clinicaltrials.gov as NCT03390296."

Journal • P1/2 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Survival and Toxicity Trade-Offs With Anthracycline-Based Induction vs Non-Anthracycline Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis (SOHO 2026) - "Anthracycline cohort (n = 9727): daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone. Nonanthracycline cohort (n = 6649): azacitidine, decitabine, venetoclax, glasdegib, gilteritinib, enasidenib, ivosidenib, midostaurin; anthracyclines excluded... Anthracycline induction was associated with 27% lower 3-year mortality but higher acute toxicity—36% more hospitalization, 23% bleeding, 13% VTE, 11% MACE—reflecting the risk-benefit profile of intensive induction. Selection of fitter patients with favorable AML biology likely contributes through residual confounding despite PSM. These findings reinforce integrating fitness, cytogenetic/molecular risk, and patient preference into the frontline regimen choice."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

Randomized Treatments for Myelodysplastic Syndrome and Related Disorders: A Comprehensive Component Network Meta-Analysis of Randomized Controlled Trials (SOHO 2026) - "Compared with best supportive care, higher odds of complete remission were observed for azacitidine, azacitidine plus lenalidomide, azacitidine plus vorinostat, panobinostat plus azacitidine, APR-246 plus azacitidine, decitabine, decitabine plus valproic acid, and glasdegib plus cytarabine. This review combines broad trial identification, structured screening, detailed extraction, and treatment level synthesis across a complex therapeutic landscape. Its findings may support future guidelines, whereas the contrast between regimen- and component-level effects leaves key clinical questions for the full review to resolve."

Retrospective data • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Early Real-World Outcomes of Revumenib Versus Venetoclax-Based Salvage Therapy in Relapsed or Refractory Acute Leukemia (SOHO 2026) - "All patients had prior AML-directed therapy before index, including hypomethylating agents, venetoclax, cytarabine, anthracyclines, gemtuzumab ozogamicin, FLT3 inhibitors, IDH inhibitors, or glasdegib. In this early real-world matched analysis, revumenib demonstrated 90-day mortality, infection risk, and acute care utilization comparable to venetoclax-based salvage therapy. In evolving AML treatment algorithms, these findings are reassuring: menin inhibition appears to be entering practice without an early excess safety signal relative to a commonly used salvage backbone. The absence of superiority should not imply equivalence but supports revumenib as a reasonable sequencing option in selected patients."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • KMT2A • NPM1

Optimizing Low-Intensity Therapeutic Strategies in Older Acute Myeloid Leukemia: A Systematic Review and Network Meta-Analysis (SOHO 2026) - "Low-intensity regimens, including hypomethylating agents (HMAs) and low-dose cytarabine (LDAC), have transformed management; however, the optimal therapeutic approach remains uncertain...Interventions: Low-intensity regimens including HMAs (azacitidine, decitabine), LDAC, and combination therapies (eg, venetoclax- or glasdegib-based regimens)...LDAC plus glasdegib showed a significant survival advantage over several LDAC-based regimens, including LDAC plus gemtuzumab ozogamicin and vosaroxin... Azacitidine combined with venetoclax appears to be the most effective low-intensity regimen for older AML patients, offering significant improvements in survival and response without substantial additional toxicity. LDAC plus glasdegib represents a promising alternative. Further head-to-head randomized trials are required to refine treatment selection and address resistance mechanisms."

Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial (ESMO 2024) - P1/2 | "The addition of GLG to standard STSC was administered safely and showed preliminary efficacy for newly diagnosed GBM, with almost 30% pts still alive at data cutoff despite the futility threshold not being surpassed. Translational research will help to define the molecular traits of long-term survivors."

Clinical • Combination therapy • P1/2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD133 • GLI1 • MGMT

Health care resource utilization and costs in patients with acute myeloid leukemia treated with posttransplant maintenance therapy. (PubMed, J Manag Care Spec Pharm) - "Patients receiving maintenance therapy were identified by a claim for 1 of the following agents after allo-HCT: azacitidine, decitabine, enasidenib, gemtuzumab ozogamicin, gilteritinib, glasdegib, ivosidenib, midostaurin, quizartinib, sorafenib, or venetoclax. Those who received maintenance therapy following allo-HCT had higher IP admission and OP use rates and incurred more pharmacy costs. These findings highlight the need to balance the clinical benefits of maintenance therapy with its increased demands on health care resources."

HEOR • Journal • Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=603 | Completed | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Active, not recruiting ➔ Completed

IO biomarker • Trial completion • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Hair loss in cancer patients receiving small molecule inhibitors: Evidence from clinical trials (AACR 2026) - "Hedgehog pathway inhibitors induced the highest overall rates, ranging from 20-30% with saridegib and glasdegib, and up to 63% with vismodegib. FGFR inhibitors (pemigatinib, infigratinib) and other kinase inhibitors (ripretinib, vemurafenib, sorafenib, AZD0424) demonstrated moderate rates (22-48%). Lower alopecia incidence was reported with aromatase inhibitors (anastrozole, lenostrozole) and the aurora B kinase inhibitor BI 811283, ranging from 9 to 21%...The higher incidences seen with Hedgehog inhibitors, compared with aromatase inhibitors, highlight how pathway-specific disruption of follicular signaling contributes to hair loss. Further research into the molecular mechanisms of these agents may help clinicians better anticipate and manage this side effect."

Clinical • Oncology • BRAF

Budget Impact of Venetoclax for Newly Diagnosed Patients with Acute Myeloid Leukemia Aged ≥ 75 Years or with Comorbidities Precluding Intensive Chemotherapy in the United States. (PubMed, Adv Ther) - "Inclusion of venetoclax combinations for newly diagnosed patients with AML aged ≥ 75 years or with comorbidities precluding intensive chemotherapy reduced the budget impact, providing potential financial benefits for US payers."

HEOR • Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=960 | Recruiting | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Not yet recruiting ➔ Recruiting | Trial completion date: Mar 2024 ➔ Oct 2024 | Initiation date: Mar 2019 ➔ Oct 2019 | Trial primary completion date: Mar 2022 ➔ Oct 2022

Enrollment open • IO biomarker • Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=960 | Not yet recruiting | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

IO biomarker • New P3 trial • Oncology • Sarcoma • Soft Tissue Sarcoma

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=603 | Active, not recruiting | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Recruiting ➔ Active, not recruiting | N=960 ➔ 603

Enrollment change • Enrollment closed • IO biomarker • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=960 | Recruiting | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2024 ➔ Oct 2025 | Trial primary completion date: Oct 2022 ➔ Oct 2023

IO biomarker • Trial completion date • Trial primary completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Dual Hedgehog/GLI1 and PI3K/Akt/mTOR Targeting Possesses Higher Efficacy to Inhibit T-Cell Acute Lymphoblastic Leukemia Growth. (PubMed, Cells) - "Cells were treated with the Gli1 inhibitor Gant-61, the Smoothened inhibitors GDC-0449 and Glasdegib, the Akt inhibitor MK-2206, and the mTOR inhibitor RAD001, both alone and in combination. These findings demonstrate a functional interaction between Hh/Gli1 and PI3K/Akt pathways in T-ALL and identify Gli1 as a critical, druggable node. Dual targeting of Gli1 and Akt represents a potential therapeutic strategy to overcome resistance and improve treatment outcomes in T-ALL."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • GLI1

MULTISARC: Molecular Profiling of Advanced Soft-tissue Sarcomas (clinicaltrials.gov) - P3 | N=603 | Active, not recruiting | Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Oct 2025 ➔ Jan 2026

IO biomarker • Trial completion date • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Daunorubicin and cytarabine liposomal (CPX-351) plus glasdegib for newly diagnosed secondary Acute Myeloid Leukemia: Results of University of California hematologic malignancies consortium trial 1913 (ASH 2025) - P2 | "Thus clearance, not just morphologic remission,may be a critical endpoint in sAML.Conclusion Despite encouraging safety/activity, the study did not meet the primary endpoint of EFS. TheCPX-351/glasdegib combination may offer benefit in sAML, particularly as a bridge to alloHCT.Encouraging responses with MRDneg rates were observed in TP53mut pts."

Acute Myelogenous Leukemia • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Neutropenia • Oncology • Respiratory Diseases • Septic Shock • TP53

Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis (ASH 2025) - "Tissue immune microenvironment analysis by multiplex IF revealed the enrichment of M2 MФand Smo+ MФ and their association with tissue fibrosis of the lung and skin, as well as skin damageseverity scores (Lee SJ, Blood, 2017) in cGVHD pts cohorts.Moreover, cGVHD mice were treated with vehicle control, Smo inhibitor (Smoi, Glasdegib), KLF4 inhibitor(KLF4i, Kenpaullone), and their combination for 28 days, starting on day 12 or 28 post-HCT forpreventative or curative therapy... Our study using mouse models and patient cohorts underscored the relevance of theHh/KLF4-dependent M2 polarization in cGVHD progression and tissue fibrosis, demonstrating thatgenetic and therapeutic targeting of Smo/KLF4-mediated M2 MФ polarization blocked the progression ofcGVHD and tissue fibrosis. Our results identified a novel mechanism of cGVHD, providing importantinsights and clinical relevance for precisely targeting M2 macrophage polarization as a new therapeuticapproach for treating cGVHD and..."

Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatology • Fibrosis • Graft versus Host Disease • Immunology • Pulmonary Disease • Respiratory Diseases • ITGAM • KLF4 • MRC1 • TGFB1

Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors. (PubMed, Front Pharmacol) - "Over the past decade, six targeted or pathway-directed small molecules-midostaurin, gilteritinib, quizartinib, ivosidenib, enasidenib, venetoclax and glasdegib-have changed frontline and relapsed/refractory (R/R) practice in genomically defined subgroups or in patients unfit for intensive chemotherapy. Here we integrate mechanistic insights with clinical evidence to: (i) map resistance biology onto targetable nodes (apoptosis control; signalling kinases; chromatin/lineage programmes; RNA splicing; DNA-damage response; nuclear export; niche adhesion and innate immune evasion); (ii) summarise the clinical trajectory and current limits of approved and emerging small molecules (including menin and LSD1 inhibitors); (iii) propose rules for rational doublets and triplets that are biologically orthogonal yet clinically tolerable; (iv) outline a regulatory timeline for key AML small molecules; and (v) prioritise where drug development should go next, including next-generation..."

Journal • Review • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations (ASH 2023) - P1 | "This study is partially supported by Astellas Pharma Global Development, Inc. The study population will include patients with AML with dual FLT3 and IDH1/IDH2 mutations R/R to initial intensive induction therapy, or for patients treated with low intensity therapy, the patient must be refractory to treatment with a single agent hypomethylating agent (HMA) or low dose cytarabine (LDAC) (at least two cycles) or an HMA/LDAC in combination with venetoclax (at least one cycle) or another standard of care therapy (e. g. gemtuzumab ozogamicin, glasdegib/LDAC). Patients with a history of autologous or allogeneic stem cell transplant for AML are permitted to participate in the study."

Clinical • Combination therapy • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • IDH1 • IDH2

Representation of Older Adults in FDA and EMA Registrational Trials for Acute Myeloid Leukemia (AML) (ASH 2024) - "Four drugs were approved in 2017 : midostaurin (ND FLT3-ITD/-TKD+ AML), enasidenib (R/R IDH2-mutated AML), CPX-351 (ND secondary-AML), and gemtuzumab ozogamicin (ND or R/R CD33+ AML)...Venetoclax combinations with decitabine/azacitidine/LDAC (newly diagnosed AML ≥75 years or unfit for IC) were approved between 2018-2020...Five trials (ivosidinib in ND, ivosidinib with azacitidine, glasdegib+LDAC, and venetoclax combined with azacitidine or LDAC) had a median age of >75 years and these trials were designed as specific to patients ≥75 years or those ineligible for IC...Trials assessing FLT3 inhibitors had a lower median age than other therapies with median ages of 48 (midostaurin), 56 (quizartinib), and 62 (gilteritinib) years on these trials...In the future, reporting of trials should include and distinguish patients both older than 65 and older than 75 for subgroup analyses. Standardization of age subgroup reporting with subpopulation analysis will better enable..."

Clinical • Acute Myelogenous Leukemia • Geriatric Disorders • Hematological Malignancies • Leukemia • Oncology • CD33 • FLT3 • IDH1 • IDH2

Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial. (PubMed, Nat Commun) - P1/2 | "Despite not surpassing the futility threshold, 30% lived at the data cutoff. Translational research will help define the molecular traits of long-term survivors."

Journal • P1/2 data • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent (ASH 2024) - "50 of 99 (65%) patients received salvage therapy which included cladribine-cytarabine-Ven (n=19), intensive induction chemotherapy (n=9), FLT3 inhibitors (n=5), Ven-HMA-FLT3 inhibitor (n=1), IDH1/2 inhibitors (n=5), glasdegib-cytarabine (n=4), gemtuzumab (n=3), lenalidomide (n=1), or investigational therapies (n=3); in addition, Ven-HMA was resumed in 14 patients in whom treatment had been discontinued for a median of 5 months (2-12). Conclusions The current study identifies male gender, TP53 mutations, and MRD status as powerful predictors of relapse and proposes a relapse prediction model for ND-AML patients receiving Ven-HMA therapy. Furthermore, relapse following Ven-HMA was associated with uniformly poor outcomes, regardless of salvage treatment strategy."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ASXL1 • DDX41 • DNMT3A • FLT3 • IDH1 • IDH2 • NPM1 • NRAS • RUNX1 • SRSF2 • TET2 • TP53

Racial Disparities in Acute Myeloid Leukemia and Myelodysplastic Syndrome US FDA Drug Approval Trials (ASH 2023) - "(Table 1) Olutasidenib, glasdegib plus low dose cytarabine, gemtuzumab-ozogamicin, liposome-encapsulated combination of daunorubicin and cytarabine, ivosidenib, and midostaurin were approved for AML. An oral combination of decitabine and cedazuridine was approved for MDS... Despite being affected adversely to a significant degree by AML, black patients are underrepresented in drug trials. More efforts should be made to include them in trials so that better treatment plans can be formulated for this underrepresented group of patients."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology

Prospective Real-World Outcomes of Acute Myeloid Leukemia (ASH 2023) - "7%) backbone and Azacitidine alone (13... Progression free survival obtained after induction therapy and overall survival were relatively shorter than the ones which were presented by other real-world registries. Lack of early access to the targeted and novel agents, like Flt3 inhibitors, Venetoclax, IDH1 and 2 inhibitors, CPX351 and Glasdegib should be a potential explanation to this relatively short PFS and OS. We have also been aware of un-ideal access to well established and nation wide cytogenetic laboratory service to induce early integration of targeted agents to the treatment and better risk stratification to determine the patients who should obtain the best prolonged survival via allo-HCT."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • IDH1